Company intelligence / Profile preview

Rockley Photonics

Oxford, United Kingdom

Ownership: Private
Development stage: Other

Overview

Rockley is conducting human clinical trials to develop FDA-approved medical grade devices. Preliminary results on noninvasive glucose monitoring showed promising accuracy in measuring blood sugar levels. The company filed for Chapter 11 bankruptcy in January 2023 but has since resumed operations and is currently sampling its Bioptx biosensing wearable with potential customers and partners.

Therapeutic areas: OncologyInfectious DiseasesOtherEndocrinology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

AppleTwo top-ten largest medical equipment and device manufacturersHengtong Group (joint venture for optical transceivers)Multiple smartphone and smartwatch makers

Beyond the preview

Go deeper on Rockley Photonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rockley Photonics.

Explore the full profile